Indicated for: type 2 diabetes mellitus
Substance: saxagliptin (DPP-4 inhibitor)
ATC: A10BH03 (Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Dipeptidyl peptidase 4 (DDP-4) inhibitors)
Saxagliptin is an antidiabetic medication from the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, used in the treatment of type 2 diabetes mellitus. It works by increasing levels of active incretins, such as GLP-1 (glucagon-like peptide-1), which stimulate insulin secretion and reduce glucagon production, thereby lowering blood glucose levels.
Saxagliptin is administered orally, usually once daily, and is indicated for patients who fail to control their blood sugar levels through diet and exercise alone. It can be used as monotherapy or in combination with other antidiabetic medications, such as metformin or sulfonylureas.
Common side effects include upper respiratory tract infections, headache, and nausea. In rare cases, severe adverse reactions such as pancreatitis or allergic reactions may occur. Regular monitoring of renal function is essential, especially in patients with renal impairment.
Saxagliptin is an effective and well-tolerated therapeutic option for patients with type 2 diabetes, contributing to improved glycemic control and reducing the risk of diabetes-related complications.